A district leader at CVS Health emphasizes that patients should get tested, be up to date with immunizations, and staying home and reach out to health care professionals when experiencing symptoms.

This new podcast will explore the latest evidence, practices, and innovations in the world of cardiovascular care from a pharmacist's point of view.

Evidence-based guidelines support the safe and effective administration of Ig therapy in clinical practice.

National Adverse Drug Event Awareness Day was established to promote awareness, drive policy changes, and encourage health care professionals and patients to prioritize medication safety.

Pharmacists can help patients with diabetes save money.

The innovative neonatal cardiac progenitor cell therapy is designed to repair heart tissue in patients with heart failure with preserved ejection fraction (HFpEF).

Specialty distribution models, including limited drug distribution systems, ensure safe medication access but can create barriers for patients, making medically integrated pharmacies essential in coordinating care.

Jeff A. Goad, PharmD, MPH, discusses the latest RSV vaccination guidelines and recommendations for 2025, highlighting vaccine options, target populations, timing considerations, evolving CDC policies, and the role of pharmacists in immunization efforts.

In a debate at the 2025 APhA Annual Meeting, speakers highlighted GLP-1s’ advantages in stroke prevention and weight loss vs SGLT2s’ superiority in heart failure, CV death reduction, and renal protection.

Two pharmacists at the 2025 APhA Annual Meeting debate the role of continuous glucose monitoring (CGM) for non-insulin users, highlighting evolving guidelines, emerging clinical evidence, cost and coverage challenges, and the need for further research to justify widespread adoption.

Contraceptive options have expanded since 1960, with pharmacists today playing a growing role as prescribers of contraception and studies showing the benefit of pharmacist-driven contraception clinics.

The study aims to address lingering public concerns, but its findings and communication have the potential to impact vaccine confidence and public health efforts.

Nakia Eldridge, PharmD, MBA, shares insights for health system and community pharmacists attending the 2025 APhA Annual Meeting & Exposition.

Patients with central nervous system (CNS) involvement achieved favorable outcomes with chimeric antigen receptor (CAR) T-cell therapy.

Non-high-density lipoprotein cholesterol was found to be more effective at predicting cardiovascular events such as stroke, myocardial outcomes, heart failure, and others compared with low-density lipoprotein cholesterol.

Sjögren's disease is one of the most common chronic autoimmune diseases that affects 4 million individuals around the world.

Allison Ju-Chen Hu, PhD and Yuhua Bao, PhD describe results of their landmark study that found significant differences in opioid prescriptions in racially and ethnically minoritized communities.

This subset of heart failure requires unique therapeutic considerations.

The new indication for guselkumab in Crohn disease builds off a previous approval in ulcerative colitis, providing patients a treatment option for the major forms of inflammatory bowel disease.

Vutrisiran becomes the first and only therapeutic FDA-approved to treat cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults.

As cases rise, experts warn that vitamin A supplementation should not be used as a replacement for vaccination.

The agent is the only approved therapy designed to address the underlying mechanisms of the disease.

The FDA reviews NDAs and BLAs to approve medications for sale and marketing in the US with decisions required by the PDUFA date.